Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Up 11.48%
As of Friday, November 13, Larimar Therapeutics, Inc.’s LRMR share price has surged by 11.48%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Rosalio Madrigal
Tudor Pop
Rosalio Madrigal
Tudor Pop
| Share Statistics | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $314.9 | $208.2 | 34% |
|
| Shares Out (Mil) | 104.7 | 55.4 | 62% |
|
| Institutional Ownership | 97.5% | 92.9% | 74% |
|
| Float (Mil) | 57.0 | 40.7 | 49% |
|
| Beta | 0.70 | 1.00 | 40% |
|
| Avg Daily Volume (000s) | 1,519 | 570 | 75% |
|
| Price Change (52-week) |
(11.4%) | 40.7% | 42% |
|
| Growth | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (31.3%) | (10.3%) | 13% |
|
| EPS (5yr) | 8.7% | 15.5% | 45 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (34.0%) | (15.7%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 4 | 8 | |
| Current EPS | ($0.333) | ($1.180) | ($0.905) | |
| Month Ago EPS | ($0.385) | ($1.351) | ($1.060) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 2 | |
| Three Months Ago EPS | ($0.385) | ($1.351) | ($1.060) | |
| Year/Year Chg | 12.1% | (48.0%) | (85.8%) | |
| Financials | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($156) | ($44) | 8% |
|
| EPS (TTM) | ($1.622) | ($1.400) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($158) | ($34) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($13) | $-0 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 22% |
|
| Enterprise Value (Q1) (Mil) | $192 | $138 | 27% |
|
| Valuation | LRMR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.09 | 1.96 | 70% |
|
| P/E | na | 17.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (95.2%) | (47.4%) | 6% |
|
| ROE | (129.8%) | (51.6%) | 7% |
|
| Liabilities to Assets | 27.8% | 29.7% | 19% |
|
| F-Score | 2 | 3 | 7% |
|
Larimar Therapeutics, Inc. did not pass any screens on 11/17/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors